Get the Stockscreener App
61.95
2.43%
1.47
After Hours:
61.95
Haemonetics Corp stock is traded at $61.95, with a volume of 530.09K.
It is up +2.43% in the last 24 hours and up +3.39% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$60.48
Open:
$60.78
24h Volume:
530.09K
Relative Volume:
0.62
Market Cap:
$2.88B
Revenue:
$1.32B
Net Income/Loss:
$175.44M
P/E Ratio:
17.02
EPS:
3.6395
Net Cash Flow:
$308.08M
1W Performance:
+4.07%
1M Performance:
+3.39%
6M Performance:
+27.52%
1Y Performance:
+6.26%
1-Day Range:
$60.51
$62.16
1-Week Range:
$56.65
$62.16
52-Week Range:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
61.95 | 2.81B | 1.32B | 175.44M | 308.08M | 3.6395 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | Needham | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Haemonetics Corp stock (US4041191090): Why its steady focus on blood management innovation matters m - AD HOC NEWS
A Look at Haemonetics Corp (HAE) After 3.4% Gain -- GF Value $86 - GuruFocus
HAE Maintained by Mizuho -- Price Target Lowered to $70 - GuruFocus
Haemonetics price target lowered to $84 from $88 at BTIG - TipRanks
Haemonetics price target lowered to $70 from $80 at Mizuho - TipRanks
Blood Bag Market Is Going to Boom| Haemonetics Corporation • Grifols S.A. • Macopharma - openPR.com
Q3 2026 Haemonetics Corp Earnings Call Transcript - GuruFocus
Q2 2026 Haemonetics Corp Earnings Call Transcript - GuruFocus
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Cuts Target Price to $64 - 富途牛牛
Haemonetics (HAE) Is Up 5.7% After FDA Expands VASCADE MVP XL Labeling for Larger EP Sheaths - simplywall.st
HAE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Haemonetics price target lowered to $64 from $70 at Citi - TipRanks
Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Weakness? - simplywall.st
Harbor Capital Advisors Inc. Sells 22,228 Shares of Haemonetics Corporation $HAE - marketbeat.com
HAE PE Ratio & Valuation, Is HAE Overvalued - Intellectia AI
Haemonetics Corporation (HAE) Stock forecasts - Yahoo Finance UK
Haemonetics will post earnings at 6 a.m., then take questions at 8 - Stock Titan
Is It Time To Reassess Haemonetics (HAE) After Prolonged Share Price Weakness - Yahoo Finance
Allspring Global Investments Holdings LLC Sells 121,063 Shares of Haemonetics Corporation $HAE - MarketBeat
Avantis U.S. Small Cap Equity Fund's Haemonetics Corp(HAE) Holding History - GuruFocus
Automatic Blood Bag Tube Stripper Market Is Going to Boom | Terumo - openPR.com
BTIG Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $88 - 富途牛牛
Haemonetics: FDA Label Expansion and New Product Launches Poised to Reignite Vascular Closure Growth by FY27 - TipRanks
Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system - TipRanks
FDA Expands Approval for Haemonetics' (HAE) VASCADE MVP XL Syste - GuruFocus
Is Haemonetics (HAE) Leveraging VASCADE MVP XL’s FDA Expansion To Deepen Its EP Moat? - simplywall.st
Haemonetics wins FDA nod for expanded vascular closure system use - Investing.com
Haemonetics Wins FDA Approval to Expand Label for VASCADE MVP XL - marketscreener.com
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System - PR Newswire
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Haemonetics stock maintained at Buy by BTIG on FDA label expansion - Investing.com South Africa
Assenagon Asset Management S.A. Sells 99,083 Shares of Haemonetics Corporation $HAE - MarketBeat
Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 29.7% - MarketBeat
Vanguard disaggregates holdings after internal realignment (NYSE: HAE) - Stock Titan
Update Recap: What drives Haemonetics Corporations stock price2026 Breakouts & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Q2 EPS Estimates for Haemonetics Boosted by Zacks Research - MarketBeat
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - simplywall.st
Q3 EPS Estimates for Haemonetics Increased by Zacks Research - MarketBeat
HAE Price Today: Haemonetics Corporation Stock Price, Quote & Chart - MEXC Exchange
Haemonetics Corp stock faces uncertainty amid lack of fresh catalysts in blood management sector - AD HOC NEWS
Why Haemonetics Stock Is Suddenly Bouncing Back - TipRanks
Hospital Solutions launch from Haemonetics aims to transform patient care standards - Traders Union
Haemonetics Corp Stock Surges on Strong Momentum Amid Plasma and Hemostasis Demand - AD HOC NEWS
Don't Get Too Worked Up Over Haemonetics's Earnings - Yahoo
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year - AOL.com
Haemonetics Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
Here's Why Haemonetics (HAE) is a Strong Value Stock - Yahoo Finance
Haemonetics Corporation (HAE) Q3 performance prompts Baird model update, price target falls to $81 - MSN
London Co. of Virginia Decreases Stake in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (HAE) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):